New selective AT2 receptor ligands encompassing a γ-turn mimetic replacing the amino acid residues 4-5 of angiotensin II act as agonists

Journal of Medicinal Chemistry

Volumn 48, Issue 12, 2005, Pages 4009-4024

  Rosenström, Ulrika ^a   Sköld, Christian ^a   Plouffe, Bianca ^b   Beaudry, Hélène ^b   Lindeberg, Gunnar ^a   Botros, Milad ^a   Nyberg, Fred ^a   Wolf, Gunter ^c   Karlén, Anders ^a   Gallo Payet, Nicole ^b   Hallberg, Anders ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF SHERBROOKE   (Canada)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR AGONIST; BENZODIAZEPINE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; UNCLASSIFIED DRUG; 1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; IMIDAZOLE DERIVATIVE; LIGAND; PYRIDINE DERIVATIVE;

AMINO ACID SUBSTITUTION; AMINO ACID SYNTHESIS; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL GROWTH; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SELECTIVITY; DRUG STRUCTURE; IN VITRO STUDY; MOLECULAR MODEL; MORPHOLOGY; MOUSE; NEURITE; NONHUMAN; RAT; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; LIVER; METABOLISM; MOLECULAR MIMICRY; MYOMETRIUM; PHYSIOLOGY; PROTEIN CONFORMATION; RADIOASSAY; SWINE; SYNTHESIS; TUMOR CELL LINE;

AMINO ACID SUBSTITUTION; ANGIOTENSIN II; ANIMALS; BENZODIAZEPINES; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; FEMALE; IMIDAZOLES; LIGANDS; LIVER; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MODELS, MOLECULAR; MOLECULAR MIMICRY; MYOMETRIUM; NEURITES; PROTEIN CONFORMATION; PYRIDINES; RADIOLIGAND ASSAY; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; SWINE;

EID: 20444372614     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0491492     Document Type: Article

References (85)

1. Kambayashi, Y.; Bardhan, S.; Takahashi, K.; Tsuzuki, S.; Inui, H.; Hamakubo, T.; Inagami, T. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J. Biol. Chem. 1993, 268, 24543-24546.
2. Mukoyama, M.; Nakajima, M.; Horiuchi, M.; Sasamura, H.; Pratt, R. E.; Dzau, V. J. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J. Biol. Chem. 1993, 268, 24539-24542.
3. Timmermans, P. B. M. W. M.; Wong, P. C.; Chiu, A. T.; Herblin, W. F.; Benfield, P.; Carini, D. J.; Lee, R. J.; Wexler, R. R.; Saye, J. A. M.; Smith, R. D. Angiotensin II receptors and angiotensin II receptor antagonists. Pharm. Rev. 1993, 45, 205-251.
4. de Gasparo, M.; Catt, K. J.; Inagami, T.; Wright, J. W.; Unger, T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharm. Rev. 2000, 52, 415-472.
5. Kaschina, E.; Unger, T. Angiotensin AT1/AT2 receptors: regulation, signaling and function. Blood Pressure 2003, 12, 70-88.
6. Horiuchi, M. Functional aspects of angiotensin type 2 receptor. Adv. Exp. Med. Biol. 1996, 396, 217-224.
7. Csikos, T.; Chung, O.; Unger, T. Receptors and their classification: focus on angiotensin II and the AT2 receptor. J. Hum. Hypertens. 1998, 12, 311-318.
8. Gendron, L.; Payet, M. D.; Gallo-Payet, N. The angiotensin type 2 receptor of angiotensin II and neuronal differentiation: from observations to mechanisms. J. Mol. Endocrinol. 2003, 31, 359-372.
9. Widdop, R. E.; Jones, E. S.; Hannan, R. E.; Gaspari, T. A. Angiotensin AT2 receptors: cardiovascular hope or hype? Br. J. Pharmacol. 2003, 140, 809-824.
10. Li, X. C.; Widdop, R. E. AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR. Br. J. Pharmacol. 2004, 142, 821-830.
11. Grady, E. F.; Sechi, L. A.; Griffin, C. A.; Schambelan, M.; Kalinyak, J. E. Expression of AT2 receptors in the developing rat fetus. J. Clin. Invest. 1991, 88, 921-933.
12. Tsutsumi, K.; Saavedra, J. M. Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am. J. Physiol. 1991, 261, R209-R216.
13. Ohkubo, N.; Matsubara, H.; Nozawa, Y.; Mori, Y.; Murasawa, S.; Kijima, K.; Maruyama, K.; Masaki, H.; Tsutumi, Y.; Shibazaki, Y.; Iwasaka, T.; Inada, M. Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997, 96, 3954-3962.
14. Chung, O.; Unger, T. Unopposed stimulation of the angiotensin AT2 receptor in the kidney. Nephrol., Dial., Transplant. 1998, 13, 537-540.
15. Kimura, B.; Sumners, C.; Phillips, M. I. Changes in skin angiotensin II receptors in rats during wound healing. Biochem. Biophys. Res. Commun. 1992, 187, 1083-1090.
16. Nio, Y.; Matsubara, H.; Murasawa, S.; Kanasaki, M.; Inada, M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J. Clin. Invest. 1995, 95, 46-54.
17. Viswanathan, M.; Saavedra, J. M. Expression of angiotensin II AT2 receptors in the rat skin during experimental wound healing. Peptides 1992, 13, 783-786.
18. Nakajima, M.; Hutchinson, H. G.; Fujinaga, M.; Hayashida, W.; Morishita, R.; Zhang, L.; Horiuchi, M.; Pratt, R. E.; Dzau, V. J. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 10663-10667.
19. Horiuchi, M.; Akishita, M.; Dzau, V. J. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999, 33, 613-621.
20. 2 receptor. Trends Endocrin. Metab. 2000, 11, 1-6.
21. Inagami, T.; Kambayashi, Y.; Ichiki, T.; Tsuzuki, S.; Eguchi, S.; Yamakawa, T. Angiotensin receptors: molecular biology and signaling. Clin. Exp. Pharmacol. Physiol. 1999, 26, 544-549.
22. 2 receptor: new insights into an old system. Regul. Pept. 2001, 99, 175-182.
23. 2 (angiotensin type 2) receptor of angiotensin II inhibit p21ras and activate MAPK (mitogen-activated protein kinase) to induce morphological neuronal differentiation in NG108-15 cells. Mol. Endocrinol. 1999, 13, 1615-1626.
24. 2 receptor stimulates ERK1 and ERK2 in quiescent but inhibits ERK in NGF-stimulated PC12W cells. Mol. Brain Res. 2000, 78, 175-180.
25. Spear, K. L.; Brown, M. S.; Reinhard, E. J.; McMahon, E. G.; Olins, G. M.; Palomo, M. A.; Patton, D. R. Conformational restriction of angiotensin II: cyclic analogues having high potency. J. Med. Chem. 1990, 33, 1935-1940.
26. 1 receptor. J. Med. Chem. 2002, 45, 1767-1777.
27. 2 receptor affinity. Bioorg. Med. Chem. 2003, 11, 2947-2954.
28. Lindman, S.; Lindeberg, G.; Gogoll, A.; Nyberg, F.; Karlen, A.; Hallberg, A. Synthesis, receptor binding affinities and conformational properties of cyclic methylenedithioether analogues of angiotensin II. Bioorg. Med. Chem. 2001, 9, 763-772.
29. Plucinska, K.; Kataoka, T.; Yodo, M.; Cody, W. L.; He, J. X.; Humblet, C.; Lu, G. H.; Lunney, E.; Major, T. C.; Panek, R. L.; Schelkum, P.; Skeean, R.; Marshall, G. R. Multiple binding modes for the receptor-bound conformations of cyclic AII agonists. J. Med. Chem. 1993, 36, 1902-1913.
30. Sugg, E. E.; Dolan, C. A.; Patchett, A. A.; Chang, R. S. L.; Faust, K. A.; Lotti, V. J. Cyclic disulfide analogues of [Sar1,Ile8]-angiotensin II. In Peptides, Chemistry, Structure Biology, Proceedings of the Eleventh American Peptide Symposium; Rivier, J. E., Marshall, G. R., Eds.; ESCOM: Leiden, The Netherlands, 1990; pp 305-306.
31. Zhang, W.-J.; Nikiforovich, G. V.; Perodin, J.; Richard, D. E.; Escher, E.; Marshall, G. R. Novel cyclic analogues of angiotensin II with cyclization between positions 5 and 7: Conformational and biological implications. J. Med. Chem. 1996, 39, 2738-2744.
32. Matsoukas, J. M.; Polevaya, L.; Ancans, J.; Mavromoustakos, T.; Kolocouris, A.; Roumelioti, P.; Vlahakos, D. V.; Yamdagni, R.; Wu, Q.; Moore, G. J. The design and synthesis of a potent angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone angiotensin II. Bioorg. Med. Chem. 2000, 8, 1-10.
33. Johannesson, P.; Lindeberg, G.; Tong, W.; Gogoll, A.; Synnergren, B.; Nyberg, F.; Karlén, A.; Hallberg, A. Angiotensin II analogues encompassing 5,9- and 5,10-fused thiazabicycloalkane tripeptide mimetics. J. Med. Chem. 1999, 42, 4524-4537.
34. Johannesson, P.; Lindeberg, G.; Tong, W.; Gogoll, A.; Karlén, A.; Hallberg, A. Bicyclic tripeptide mimetics with reverse turn inducing properties. J. Med. Chem. 1999, 42, 601-608.
35. Hruby, V. J.; Balse, P. M. Conformational and topographical considerations in designing agonist peptidomimetics from peptide leads. Curr. Med. Chem. 2000, 7, 945-970.
36. Hruby, V. J. Designing peptide receptor agonists and antagonists. Nat. Rev. Drug Discovery 2002, 1, 847-858.
37. Samanen, J. M.; Peishoff, C. E.; Keenan, R. M.; Weinstock, J. Refinement of a molecular model of angiotensin II (AII) employed in the discovery of potent nonpeptide antagonists. Bioorg. Med. Chem. Lett. 1993, 3, 909-914.
38. Nikiforovich, G. V.; Kao, J. L. F.; Plucinska, K.; Zhang, W. J.; Marshall, G. R. Conformational analysis of two cyclic analogues of angiotensin: implications for the biologically active conformation. Biochemistry 1994, 33, 3591-3598.
39. Nikiforovich, G. V.; Marshall, G. R. Three-dimensional recognition requirements for angiotensin agonists: a novel solution for an old problem. Biochem. Biophys. Res. Commun. 1993, 195, 222-228.
40. Joseph, M. P.; Maigret, B.; Scheraga, H. A. Proposals for the angiotensin II receptor-bound conformation by comparative computer modeling of AII and cyclic analogues. Int. J. Pept. Protein Res. 1995, 46, 514-526.
41. Balodis, J.; Golbraikh, A. Conformational analysis of cyclic angiotensin II analogues. Lett. Pept. Sci. 1996, 3, 195-199.
42. Carpenter, K. A.; Wilkes, B. C.; Schiller, P. W. The octapeptide angiotensin II adopts a well-defined structure in a phospholipid environment. Eur. J. Biochem. 1998, 251, 448-453.
43. 1 non-peptide antagonists. Bioorg. Med. Chem. 2001, 9, 1639-1647.
44. Boucard, A. A.; Wilkes, B. C.; Laporte, S. A.; Escher, E.; Guillemette, G.; Leduc, R. Photolabeling identifies position 172 of the human AT1 receptor as a ligand contact point: receptor-bound angiotensin II adopts an extended structure. Biochemistry 2000, 39, 9662-9670.
45. Schmidt, B.; Lindman, S.; Tong, W.; Lindeberg, G.; Gogoll, A.; Lai, Z.; Thornwall, M.; Synnergren, B.; Nilsson, A.; Welch, C. J.; Sohtell, M.; Westerlund, C.; Nyberg, F.; Karlen, A.; Hallberg, A. Design, synthesis, and biological activities of four angiotensin II receptor ligands with γ-turn mimetics replacing amino acid residues 3-5. J. Med. Chem. 1997, 40, 903-919.
46. Printz, M. P.; Nemethy, G.; Bleich, H. Proposed models for angiotensin II in aqueous solution and conclusions about receptor topography. Nature (London) 1972, 237, 135-140.
47. Lindman, S.; Lindeberg, G.; Nyberg, F.; Karlén, A.; Hallberg, A. Comparison of three γ-turn mimetic scaffolds incorporated into angiotensin II. Bioorg. Med. Chem. 2000, 8, 2375-2383.
48. Deraët, M.; Rihakova, L.; Boucard, A.; Perodin, J.; Sauve, S.; Mathieu, A. P.; Guillemette, G.; Leduc, R.; Lavigne, P.; Escher, E. Angiotensin II is bound to both receptors AT1 and AT2, parallel to the transmembrane domains and in an extended form. Can. J. Physiol. Pharmacol. 2002, 80, 418-425.
49. Miura, S.-I.; Karnik, S. S. Angiotensin II type 1 and type 2 receptors bind angiotensin II through different types of epitope recognition. J. Hypertens. 1999, 17, 397-404.
50. Samanen, J.; Regoli, D. Structure-activity relationships of peptide angiotensin II receptor agonists and antagonists. In Angiotensin II Receptors, Volume I: Molecular Biology, Biochemistry, Pharmacology and Clinical Perspectives; Ruffolo, R. R., Jr., Ed.; CRC Press: Boca Raton, FL, 1994; pp 11-97.
51. Bouley, R.; Perodin, J.; Plante, H.; Rihakova, L.; Bernier, S. G.; Maletinska, L.; Guillemette, G.; Escher, E. N- and C-terminal structure-activity study of angiotensin II on the angiotensin AT2 receptor. Eur. J. Pharmacol. 1998, 343, 323-331.
52. Cody, W. L.; He, J. X.; Lunney, E. A.; Humblet, C. C.; Lu, G. H.; Panek, R. L.; Dudley, D. T. Modification of the C-terminal dipeptide of angiotensin II yielded a novel series of analogues with II (AT2) receptor selectivity. Protein Pept. Lett. 1996, 3, 107-112.
53. Speth, R. C.; Kim, K. H. Discrimination of two angiotensin II receptor subtypes with a selective agonist analogue of angiotensin II, p-aminophenylalanine6 angiotensin II. Biochem. Biophys. Res. Commun. 1990, 169, 997-1006.
54. Aiyar, N.; Griffin, E.; Edwards, R.; Weinstock, J.; Samanen, J.; Nambi, P. Characterization of bovine ovary angiotensin II receptors using subtype-selective antagonists. Pharmacology 1993, 46, 1-8.
55. Samanen, J.; Aiyar, N.; Edwards, R. Modifications to angiotensin II (AII) peptide analogues that reduce AT1 receptor affinity have little to no effect upon AT2 receptor affinity. In Peptides, Proceedings of the Thirteenth American Peptide Symposium; Hodges, R. S., Smith, J. A., Eds.; ESCOM: Leiden, The Netherlands, 1994; pp 640-642.
56. 2 receptor binding properties of angiotensin II analogues. J. Pept. Res. 2004, 64, 194-201.
57. 2-selective angiotensin II analogues encompassing tyrosine functionalized 5,5-bicyclic thiazabicycloalkane dipeptide mimetics. J. Med. Chem. 2004, 47, 6009-6019.
58. 2 receptor ligand with a γ-turn-like mimetic replacing the amino acid residues 4-5 of angiotensin II. J. Med. Chem. 2004, 47, 859-870.
59. Marshall, G. R. Determination of the receptor bound conformation of angiotensin. Dtsch. Apoth. Ztg. 1986, 126, 2783-2786.
60. Uenishi, J. i.; Kobayashi, N.; Komine, S.; Okadai, T.; Yonemitsu, O.; Sasaki, T.; Yamada, Y. Total synthesis of (±)-acetomycin and design of esterase-resistant analogues. Chem. Pharm. Bull. 1999, 47, 517-523.
61. Dudley, D. T.; Panek, R. L.; Major, T. C.; Lu, G. H.; Bruns, R. F.; Klinkefus, B. A.; Hodges, J. C.; Weishaar, R. E. Subclasses of angiotensin II binding sites and their functional significance. Mol. Pharmacol. 1990, 38, 370-377.
62. Nielsen, A. H.; Schauser, K; Winther, H.; Dantzer, V.; Poulsen, K. Angiotensin II receptors and renin in the porcine uterus: myometrial AT2 and endometrial AT1 receptors are down-regulated during gestation. Clin. Exp. Pharmacol. Physiol. 1997, 24, 309-314.
63. Buisson, B.; Bottari, S. P.; De Gasparo, M.; Gallo-Payet, N.; Payet, M. D. The angiotensin AT2 receptor modulates T-type calcium current in nondifferentiated NG108-15 cells. FEBS Lett. 1992, 309, 161-164.
64. Laflamme, L.; de Gasparo, M.; Gallo, J.-M.; Payet, M. D.; Gallo-Payet, N. Angiotensin II induction of neurite outgrowth by AT2 receptors in NG108-15 cells. Effect counteracted by the AT1 receptors. J. Biol. Chem. 1996, 271, 22729-22735.
65. Gendron, L.; Cote, F.; Payet, M. D.; Gallo-Payet, N. Nitric oxide and cyclic GMP are involved in angiotensin II AT2 receptor effects on neurite outgrowth in NG108-15 cells. Neuroendocrinology 2002, 75, 70-81.
66. Wolf, G.; Harendza, S.; Schroeder, R.; Wenzel, U.; Zahner, G.; Butzmann, U.; Freeman, R. S.; Stahl, R. A. K. Angiotensin II's antiproliferative effects mediated through AT2-receptors depend on down-regulation of SM-20. Lab. Invest. 2002, 82, 1305-1317.
67. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The protein data bank. Nucleic Acids Res. [Online] 2000, 28, 235-242. http://www.pdb.org/.
68. Martin, Y. C.; Bures, M. G.; Danaher, E. A.; DeLazzer, J.; Lico, I.; Pavlik, P. A. A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists. J. Comput.-Aided Mol. Des. 1993, 7, 83-102.
69. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. MacroModel - an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 1990, 11, 440-467.
70. Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical treatment of solvation for molecular mechanics and dynamics. J. Am. Chem. Soc. 1990, 112, 6127-6129.
71. Knowle, D.; Kurfis, J.; Gavini, N.; Pulakat, L. Role of Asp297 of the AT2 receptor in high-affinity binding to different peptide ligands. Peptides 2001, 22, 2145-2149.
72. Heerding, J. N.; Yee, D. K.; Jacobs, S. L.; Fluharty, S. J. Mutational analysis of the angiotensin II type 2 receptor: contribution of conserved extracellular amino acids. Regul. Pept. 1997, 72, 97-103.
73. Blankley, C. J.; Hodges, J. C.; Mutchko, S. R.; Himmelsbach, R. J.; Chucholowski, A.; Connolly, C. J.; Neergaard, S. J.; Van Nieuwenhze, M. S.; Sebastian, A.; Quin, J., III.; Essenburg, A. D.; Cohen, D. M. Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype. J. Med. Chem. 1991, 34, 3248-3260.
74. Whitebread, S.; Mele, M.; Kamber, B.; de Gasparo, M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem. Biophys. Res. Commun. 1989,163, 284-291.
75. 2 receptor agonist. J. Med. Chem. 2004, 47, 5995-6008.
76. Kivlighn, S. D.; Huckle, W. R.; Zingaro, G. J.; Rivero, R. A.; Lotti, V. J.; Chang, R. S. L.; Schorn, T. W.; Kevin, N.; Johnson, R. G., Jr. Discovery of L-162,313: a nonpeptide that mimics the biological actions of angiotensin II. Am. J. Physiol. 1995, 268, R820-R823.
77. Perlman, S.; Schambye, H. T.; Rivero, R. A.; Greenlee, W. J.; Hjorth, S. A.; Schwartz, T. W. Non-peptide angiotensin agonist. Functional and molecular interaction with the AT1 receptor. J. Biol. Chem. 1995, 270, 1493-1496.
78. 2 receptor agonist in vivo. J. Med. Chem. 2004, 47, 1536-1546.
79. Rovnyak, G.; Andersen, N.; Gougoutas, J.; Hedberg, A.; Kimball, S. D.; Malley, M.; Moreland, S.; Porubcan, M.; Pudzianowski, A. Studies directed toward ascertaining the active conformation of 1,4-dihydropyridine calcium entry blockers. J. Med. Chem. 1988, 31, 936-944.
80. Ricci, A.; Martani, A.; Graziani, O.; Oliva, M. L. Benzisothiazoles. II. Oxidation and nitration. Ann. Chim. (Rome) 1963, 53, 1860-1868.
81. 50) of an enzymic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
82. Goodman, J. M.; Still, W. C. An unbounded systematic search of conformational space. J. Comput. Chem. 1991, 12, 1110-1117.
83. Hobohm, U.; Scharf, M.; Schneider, R.; Sander, C. Selection of representative protein data sets. Protein Sci. 1992, 1, 409-417.
84. Hobohm, U.; Sander, C. Enlarged representative set of protein structures. Protein Sci. 1994, 3, 522-524.
85. SYBYL Molecular Modeling Software, version 6.9; Tripos Inc.: St. Louis, MO.